Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-02-02
Target enrollment:
Participant gender:
Summary
This is a phase Ia, single-center, open label, dose escalation clinical study to evaluate the
safety, tolerability, pharmacokinetics, immunogenicity and anti-tumor efficacy of MW11 (a
recombinant humanized anti-PD-1 monoclonal antibody) for injection in patients with advanced
solid tumors.